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Background. The effects of anaesthetics on left ventricular (LV) diastolic function in patients
with pre-existing diastolic dysfunction are not well known. We hypothesized that propofol but
not sevoflurane will worsen the pre-existing LV diastolic dysfunction.
Methods. Of 24 randomized patients, 23 fulfilled the predefined echocardiographic criterion
for diastolic dysfunction. They received general anaesthesia with sevoflurane 1 MAC (n=12) or
propofol 4 mg ml1 (n=11). Echocardiographic examinations were performed at baseline and in
anaesthetized patients under spontaneous breathing and under positive pressure ventilation.
Analysis focused on peak early diastolic velocity of the mitral annulus (Ea).
Results. During spontaneous breathing, Ea was higher in the sevoflurane than in the propofol
group [mean (95% CI) 7.0 (5.9–8.1) vs 5.5 (4.7–6.3) cm s1; P<0.05], reflecting an increase of Ea
from baseline only in the sevoflurane group (P<0.01). Haemodynamic findings were similar in both
groups, but the end-tidal carbon dioxide content was more elevated in the propofol group
(P<0.01). During positive pressure ventilation, Ea was similarly low in the sevoflurane and propofol
groups [5.3 (4.2–6.3) and 4.4 (3.6–5.2) cm s1, respectively].
Conclusions.During spontaneous breathing, early diastolic function improved in the sevoflurane
but not in the propofol group. However, during positive pressure ventilation and balanced
anaesthesia, there was no evidence of different effects caused by the two anaesthetics.
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Introduction
Diastolic dysfunction is closely related to reduced exercise
tolerance, dyspnoea and increased mortality.1 2 During dia-
stole, dissociation of calcium from troponin C and active
re-uptake of calcium into the sarcoplasmic reticulum are key
processes of myosin detachment from actin, causing
myocardial relaxation.3 Many anaesthetics including
sevoflurane and propofol alter calcium homeostasis at sev-
eral subcellular targets, for example the re-uptake of cal-
cium into the sarcoplasmic reticulum.4–6 These interactions
are regarded as the molecular basis for alterations of dia-
stolic and systolic functions caused by anaesthetics. How-
ever, little is known about the effects of anaesthetics on
diastolic function in vivo; current knowledge is mainly
based on animal and laboratory studies7 that show impair-
ment of left ventricular (LV) diastolic function by inhala-
tional anaesthetics8–10 but no effect on diastolic function by
propofol.11 12 In contrast, our recent study in healthy humans
failed to detect any impairment of diastolic function by
halothane and sevoflurane but found a slight impairment
by propofol.13
Given the conflicting findings and the paucity of data in
patients, this study was designed to evaluate the effects of
sevoflurane and propofol on LV diastolic function in
patients with pre-existing diastolic dysfunction but pre-
served LV systolic function. Pre-existing diastolic dysfunc-
tion was assumed in patients with aortic stenosis undergoing
aortic valve replacement who had preserved LV systolic
function. However, for study inclusion these patients had
to fulfil an echocardiographic criterion of LV diastolic dys-
function, that is reduced peak early diastolic velocity of the
mitral annulus (Ea).
14 15 Based on our previous findings in
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healthy subjects,13 we hypothesized that sevoflurane would
have no negative effect on LV diastolic function whereas we
expected propofol to impair early diastolic function, as indi-
cated by a further decrease in Ea. This hypothesis was tested
in two experimental conditions, that is anaesthesia with
single agent and spontaneous breathing (step I), and bal-
anced anaesthesia and positive pressure ventilation (step II),
as commonly performed in clinical practice.
Methods
The institutional Review Board at the University of Basel
Hospital approved the study for which patients with valvular
aortic stenosis undergoing aortic valve replacement were
eligible. Exclusion criteria were more than mild aortic
valve regurgitation, ejection fraction <50%, coronary artery
or cerebral vascular disease, pulmonary disease under chro-
nic medication, age <18 or >75 yr, or BMI >30 kg m2.
Patients were only included in the study if they fulfilled a
previously published echocardiographic criterion of
diastolic dysfunction, that is, if peak early diastolic velocity
of the septal annulus (Ea sept) was <8.5 cm1.14 15 Twenty-
four patients were enrolled after obtaining their informed
written consent. Patients were randomly assigned to under-
go anaesthesia with either sevoflurane or propofol. A
computer-generated random list was used.
After arrival in the preoperative area, i.v. access was
established and Ringer’s lactate administered to replace
the fluid deficit caused by overnight fasting. The deficit
per hour of fasting was calculated as follows: 4 ml kg1
for the first 10 kg of body weight, 2 ml kg1 for the second
10 kg and 1 ml kg1 for every additional kilogram of weight.
Twenty-five per cent of the deficit was replaced before the
start of the study, a total of 30% by the end of anaesthesia
step I (see below) and a total of 35% by the end of anaes-
thesia step II (see below). Two-lead electrocardiography,
pulse oximetry and invasively measured arterial pres-
sure (PCMS Workstation 90308-15-03, SpaceLabs Inc.,
Redmond, WA, USA), and the bispectral index (BIS; Aspect
1000, Aspect Medical Systems Inc., Natick, MA, USA;
software version 1.01) were monitored continuously. As
soon as the patient was anaesthetized, end-tidal concentra-
tions of carbon dioxide and sevoflurane were measured con-
tinuously at the tip of the laryngeal mask or orotracheal tube
(Caponomac Ultima, Datex, Helsinki, Finland). A decrease
in systolic arterial pressure >30% from baseline was defined
as clinically relevant hypotension and treated with a single
or repeated i.v. bolus of phenylephrine 25 mg.
The first transthoracic echocardiography (TTE) was per-
formed in an awake, unpremedicated patient (baseline data)
in a partial left lateral position. The same position was
used during all further echocardiographic examinations.
Thereafter, anaesthesia was induced by inhalation of
sevoflurane (Sevorane, Abbott International Ltd., Abbott
Park, IL, USA) in 100% oxygen or by i.v. infusion of pro-
pofol (Diprivan, Zeneca Pharmaceuticals, Macclesfield,
Cheshire, UK) delivered by a target-controlled infusion
system (TCI, Diprifusor, Zeneca Pharmaceuticals). No
other narcotics or opioids were used. After placement of
a laryngeal mask, the inspiratory oxygen concentration was
adjusted to 0.4 and the administration of anaesthetics was
reduced to 1 MAC of the inhalational anaesthetic (2% end-
tidal concentration of sevoflurane), or to propofol 4 mg
ml1. As soon as anaesthetic and haemodynamic steady-
state conditions were reached, a second TTE was performed
(step I). At the end of steps I and II, blood was withdrawn
from the arterial line in patients of the propofol group for
chromatographic analysis of propofol blood concentrations
(modified from Plummer and collegues16).
After finishing step I, fentanyl 2 mg kg1 and rocuronium
0.6 mg kg1 were administered and the patient’s trachea was
intubated. Intermittent positive pressure ventilation (IPPV)
was performed to achieve normoventilation (end-tidal car-
bon dioxide content 4.5–5 kPa). A transoesophageal echo
probe was then placed in the oesophagus.
As soon as steady-state conditions were reached at
1 MAC of sevoflurane or i.v. propofol 4 mg ml1, a trans-
oesophageal echocardiography (TOE) was performed
(step II). After finishing this examination, each patient
underwent aortic valve replacement.
All echocardiograms were obtained with a Sonos 5500
ultrasonographic system (Philips Medical Systems, Best,
The Netherlands) according to current guidelines.17–19
For TTE, a 1.8–2.1/3.6–4.1 MHz S4 probe was used, and
for TOE a 4–7 MHz multiplane probe. The echocardio-
graphic data were digitally stored for subsequent off-line
analysis. Standard LV short-axis and two- and four-chamber
views were obtained by the parasternal and apical views for
TTE and by standard midoesophageal and transgastric views
for TOE. For recordings of pulsed-wave tissue Doppler
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Fig 1 Pulsed-wave Doppler tissue imaging of the septal mitral annulus.
The position of the pulsed-wave Doppler sample volume is demonstrated
in the two-dimensional echocardiographic transthoracic image of the
apical four-chamber view in the upper part of the figure. LA=left atrium;
LV=left ventricle; Ea sept=peak early diastolic velocity of septal mitral
annulus; Aa sept=peak late diastolic velocity of septal mitral annulus;
Sa sept=peak systolic velocity of septal mitral annulus.
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imaging, the sample volume was placed at the septal and
lateral sides of the mitral annulus and the acoustic power
and the filter frequencies of the system set to the lowest
possible values (Fig. 1). The main echocardiographic
indicator of early diastolic function was predefined as the
average of the peak early diastolic peak velocity of septal
and the lateral mitral annulus (Ea).
14 15 The comprehensive
echocardiographic assessment included measurement of the
following variables: peak early (Ea) and late (Aa) diastolic,
and peak systolic (Sa) velocities of septal and lateral mitral
annuli, peak early (E) and peak late (A) transmitral filling
velocities, deceleration time (DT) of E, isovolumic relaxa-
tion time (IVRT), and end-diastolic (EDA) and end-systolic
(ESA) areas. From these data, the following parameters
were calculated: the ratios of E/A and E/Ea and the fractional
area change {FAC=[(EDAESA)/EDA]·100}. All vari-
ables were measured at end-expiration over three preferably
consecutive cardiac cycles and averaged by an experienced
physician-echocardiographer blinded to all other study data.
To determine intra-observer and interobserver variability, a
random sample of 25% of the tissue Doppler recordings was
submitted twice to the first investigator and once to a second
investigator. The variabilities then were calculated as the
mean absolute difference between both readings divided by
their mean and expressed as a percentage.
Continuous variables are presented as mean and 95% CIs.
The Fisher’s exact test was used for analyses of dichoto-
mous variables. Continuous variables were compared by
using non-parametric tests: the Mann–Whitney test was
used for comparisons between the two study groups at
the different steps of the study. The Wilcoxon test was
used for comparison of the findings at baseline vs anaesthe-
sia step I within one study group. Comparisons during step II
were only performed between the study groups because of
the different echocardiographic techniques used at step I
(TTE) and step II (TOE). P<0.05 was considered statisti-
cally significant. All statistical analyses were performed
using a SPSS for Windows 11.5 computer package (SPSS
Inc., Chicago, IL, USA). The sample size calculation was
based on our previous study13 estimating that 12 patients per
group would allow for detection of a 25% difference in Ea
with a power of 80% for intragroup comparison and of a
33% difference in Ea for intergroup comparisons.
Results
One patient in the propofol group had Ea >8.5 cm s1 and
was excluded from analysis, thus leaving 11 patients in the
propofol and 12 patients in the sevoflurane group. Both
groups had similar patients’ characteristics (Table 1) and
similar baseline findings (Table 2 and Appendix).
From baseline to anaesthesia step I, Ea increased in the
sevoflurane group (P<0.01) but remained unchanged in the
propofol group. This resulted in a higher Ea in the sevoflu-
rane group than in the propofol group (P<0.05; Table 2 and
Fig. 2). Accordingly, the Ea/Aa ratio was higher in the
Table 1 Patient characteristics. Values are mean (95% CI) or numbers.
There were no differences between the groups. ACE, angiotensin converting
enzyme
Sevoflurane (n=12) Propofol (n=11)
Women 4 4
Age (yr) 61 (52–69) 63 (58–69)
Weight (kg) 71 (64–79) 75 (68–82)
Height (cm) 168 (163–172) 167 (162–173)
BMI (kg m2) 25 (23–28) 27 (25–29)
Haemoglobin (g litre1) 142 (131–154) 147 (137–156)
Creatinine (mmol litre1) 69 (57–80) 76 (69–83)
Chronic medication
b-receptor blockers 1 3
ACE inhibitors 2 1
Diuretics 2 2
Table 2 Pulsed-wave tissue Doppler findings at baseline and during anaesthesia
with sevoflurane 1 MAC, or propofol 4 mg ml1 under spontaneous ventilation
(step I). Values are mean (95% CI). There were no differences between the
groups in baseline findings. *P<0.05 baseline vs step I (within-group compari-
son). §P<0.05 sevoflurane vs propofol (between-group comparison). Ea, peak
early diastolic velocity of the mitral annulus; Aa, peak late diastolic velocity of
the mitral annulus; Sa, peak systolic velocity of the mitral annulus
Sevoflurane Propofol
Baseline Anaesthetized
spontaneous
breathing
Baseline Anaesthetized
spontaneous
breathing
Ea (cm s
1) 6.2 (5.3–7.1) 7.0 (5.9–8.1)* 5.5 (4.4–6.6) 5.5 (4.7–6.3)§
Aa (cm s
1) 10.3 (9.0–11.5) 7.7 (6.7–8.7)* 9.0 (7.6–10.4) 8.6 (7.8–9.3)
Ea/Aa 0.6 (0.5–0.8) 1.0 (0.8–1.2)* 0.6 (0.5–0.8) 0.7 (0.5–0.8)§
Sa (cm s
1) 7.1 (6.5–7.6) 5.9 (5.4–6.5)* 6.5 (5.8–7.3) 6.5 (5.7–7.3)
−4.0 −3.0 −2.0 −1.0 0.0 1.0 2.0
Ea
Aa
Ea/Aa
Sa
cm s−1
Fig 2 Mean changes and 95% CIs of tissue Doppler derived variables
of the mitral annulus from baseline to anaesthesia with 1 MAC
sevoflurane (open triangle) or 4 mg ml1 propofol (filled square) under
spontaneous breathing (step I). Ea=peak early diastolic velocity of the
mitral annulus; Aa=peak late diastolic velocity of the mitral annulus;
Sa=peak systolic velocity of the mitral annulus.
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sevoflurane than in the propofol group, whereas there was no
difference in Aa or Sa between the groups. In the sevoflurane
group, the mitral inflow patterns changed (evident as a
decrease in A and an increase in the E/A ratio) and the
IVRT tended to decrease. In the propofol group, all these
variables remained unchanged. However, there were no sig-
nificant differences between the groups. The haemodynamic
variables and the E/Ea ratio were similar in both study
groups, as were the number (4 vs 6) and dosage (2.4 vs
1.9 mg kg1) of phenylephrine administered, and the BIS
values. However, end-tidal carbon dioxide was lower in the
sevoflurane than in the propofol group [mean (95% CI) 6.2
(5.7–6.8) kPa and 7.1 (6.7–7.5) respectively; P<0.01]. These
data are shown in detail in the Appendix.
During anaesthesia and IPPV, there was no difference in
Ea between the study groups, and Aa and Sa were also similar
(Table 3). However, the Ea/Aa ratio was higher in the
sevoflurane group. The haemodynamic findings, the E/Ea
ratio, the mitral inflow patterns, the number (9 vs 8) and the
dosage (5.3 vs 6.2 mg kg1) of administered phenylephrine,
end-tidal carbon dioxide and the BIS values were similar in
both groups (Appendix).
The intra-observer variability for Ea was 4.3% (2.2–5.9)
for data obtained by TTE and 3.0% (0–6.2) for data obtained
by TOE. The corresponding values for the interobserver
variability were 4.8% (2.5–7.1; TTE) and 4.3% (0–9.2; TOE).
Discussion
This study investigated the effects of sevoflurane and propo-
fol on LV diastolic function in patients with pre-existing
diastolic dysfunction but preserved systolic function. During
spontaneous breathing and consecutive elevation of end-
tidal carbon dioxide, sevoflurane slightly improved early
diastolic function whereas propofol had no detectable effect.
In contrast, IPPV and normal end-tidal carbon dioxide the
early diastolic function in both the groups was similarly
impaired.
This study used two experimental settings to test the
effects of sevoflurane and propofol on diastolic function.
The first setting (spontaneous breathing) allowed for per-
forming anaesthesia solely with the one anaesthetic and to
avoid the effect of IPPV on venous pooling, preload and
afterload. However, spontaneous breathing resulted in an
inevitable elevation of end-tidal carbon dioxide and, more-
over, it does not represent common clinical practice. In con-
trast, the second setting (balanced anaesthesia and IPPV),
maintains normocapnia. It is unknown whether the observed
changes were caused only by the drug under primary
investigation or were also influenced by opioids, neuro-
muscular blocking drugs, muscular paralysis and/or the
consequences of IPPV.
The present finding that sevoflurane alone had a favour-
able effect on diastolic function in patients with pre-existing
diastolic dysfunction is in agreement with our previous find-
ing in healthy subjects.13 These findings in man conflict with
most animal and in vitro studies reporting marked changes
in myocardial relaxation and diastolic filling induced by
inhalational anaesthetics.8–10 20 These previous findings
were explained by the interference of inhalational anaes-
thetics with calcium re-uptake from the cytosol into the
sarcoplasmatic reticulum during diastole,5 a key mechanism
of myocardial relaxation.3 However, there are important
differences between our study and previous studies that
might explain the conflicting results. Most importantly,
the previous studies investigated healthy animals9 10 20 or
isolated hearts from healthy animals,8 and some studies
used higher doses of inhalational anaesthetics8 or adminis-
tered additional drugs for induction of anaesthesia.9 In con-
trast, our study evaluated patients with pre-existing
impairment of diastolic function, used the clinical dose of
anaesthetics, did not use drugs other than that under invest-
igation for induction of anaesthesia (step I) and assessed
diastolic function non-invasively by Doppler echocardio-
graphy according to current cardiological guidelines.17 18
A finding consistent with previous studies20 was that
sevoflurane impaired systolic atrial and ventricular func-
tions, as indicated by decreases of Sa and Aa. In contrast,
these variables were unchanged during propofol anaesthe-
sia, indicating no effect of propofol on systolic function.
The present result that propofol alone had no unfavourable
effect on diastolic function in patients with pre-existing dias-
tolic dysfunction is in agreement with most previous ani-
mal11 12 and human21 studies. A recently published study
found no effect of low-dose propofol on echocardiographic
parameters of diastolic function during conscious sedation of
patients with pre-existing diastolic dysfunction.21
Only three studies reported impairment of diastolic func-
tion by propofol.13 22 23 As with sevoflurane, such an effect
on diastolic function can be explained by intracellular effects
of the anaesthetic: propofol impairs re-uptake of calcium by
the sarcoplasmatic reticulum6 24 and modulates phosphory-
lation of the contractile muscles,25 which are the mechanisms
directly involved in myocardial muscle relaxation. In rabbits
with cardiac hypertrophy, there was impairment of diastolic
function by propofol but only at supraclinical doses,22 while
in a dog model of dilated cardiomyopathy there was impair-
ment of early diastolic LV filling.23
In our previous study, we found mild impairment of
diastolic function by propofol in spontaneously breath-
ing healthy young subjects, which was based on a slight
Table 3 Pulsed-wave tissue Doppler findings during anaesthesia with sevoflu-
rane 1 MAC, or propofol 4 mg ml1 and IPPV (step II). Values are mean
(95% CI). §P<0.05 sevoflurane vs propofol, (between-group comparison).
Ea, peak early diastolic velocity of the mitral annulus; Aa, peak late diastolic
velocity of the mitral annulus; Sa, peak systolic velocity of the mitral annulus
Sevoflurane Propofol
Ea (cm s
1) 5.3 (4.2–6.3) 4.4 (3.6–5.2)
Aa (cm s
1) 4.1 (3.4–4.7) 5.3 (4.4–6.3)
Ea/Aa 1.4 (0.9–1.9) 0.9 (0.6–1.1)§
Sa (cm s
1) 4.6 (3.9–5.3) 4.7 (3.8–5.6)
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decrease in Ea and an increase in heart-rate corrected
IVRT.13 We considered this observed impairment of dia-
stolic function by propofol to be too small to be the cause of
clinical concern.13 Similarly, the present results also do
not support the clinical importance of the intracellular
effects of propofol, although we again found a prolonged
IVRT in the propofol group during spontaneous breathing.
The predefined outcome variable, the tissue Doppler
imaging indicator Ea, did not change during propofol anaes-
thesia in spontaneously breathing patients. Although IVRT
is one of the traditional echocardiographic indicators of
diastolic function,18 we did not focus on this in this study
because Ea has three important advantages: Its main advan-
tage in patients with pre-existing diastolic function is that
Ea has a unimodal distribution
14 15 with a gradual decrease
in going from mild to severe diastolic dysfunction.26 This
characteristic implies that an increase in Ea indicates
improvement, while a decrease in Ea reflects impairment
of diastolic function. In contrast, changes in IVRT (and
similarly in the transmitral E/A ratio) are U-shaped during
transition from normal diastolic function to severe diastolic
dysfunction.14 In patients with pre-existing diastolic dys-
function, as studied here, this characteristic implies that
an increase in IVRT (or in the E/A ratio) is equivocal
and can indicate either improvement or deterioration. A
second advantage of Ea is that it is less load-dependent
than IVRT,26 while the third advantage of Ea is that it
closely correlates with the time constant of the decrease
in LV pressure t,15 27 the invasive gold standard of evalu-
ation of LV relaxation. In cardiac patients, Ea has been
widely used to define the presence and severity of diastolic
dysfunction.2 14 15 17
As expected during spontaneous breathing in anaes-
thetized patients, end-tidal carbon dioxide was elevated in
both study groups, the elevation being more pronounced in
the propofol group. To what extent these changes altered the
myocardial calcium homoeostasis, as shown in vitro using a
high carbon dioxide load,28 those altering the effects of the
anaesthetic agents cannot be determined from our clinical
investigation.
There were no differences in Ea between the sevoflurane
and the propofol group during balanced anaesthesia, IPPV
and normocapnia. This result agrees with our previous study
in healthy subjects during balanced anaesthesia with
sevoflurane and propofol that also found no difference in
Ea during IPPV.
13 However, in both study groups early
diastolic function remained impaired, as indicated by the
low Ea values.
Potential reasons for the different findings during single-
agent anaesthesia and spontaneous breathing vs balanced
anaesthesia and IPPV cannot be differentiated by the experi-
mental design used. Reasons may include different concen-
trations of carbon dioxide, the addition of opioids and
neuromuscular blocking drugs, muscular paralysis and/or
the consequences of IPPV. The haemodynamic effect of
opioids such as fentanyl might depend on concomitant
drug administration.29 Because TTE often does not allow
for optimal image quality during IPPV, we used TOE during
this study step. However, the difference in echocardio-
graphic technique between TTE and TOE makes direct
comparison of the findings questionable, and we did not
perform statistical comparisons of the TTE and TOE derived
findings.
This study has some limitations. First, the results derived
from patients of this study cannot necessarily be extrapo-
lated to patients with other than isolated non-ischaemic
diastolic dysfunction. The second limitation of this study
is that the equipotency of propofol and sevoflurane can be
questioned. However, the similar BIS values in both groups
and the comparable haemodynamics indicated a similar
‘depth’ of anaesthesia and, accordingly, equipotency.
Thirdly, invasively derived information on the decrease
in LV isovolumic pressure or its time constant t was not
available. However, Ea is a well-validated echocardio-
graphic parameter of diastolic function14 15 and closely cor-
relates with t.15 27 Ea is widely used in TTE and its
feasibility by TOE has been recently demonstrated.13 30
In addition, the E/Ea ratio, an echocardiographic parameter
of LV filling pressure,31 did not change throughout the
study. Finally, one might speculate that the low Ea values
during IPPV were caused by clinically undetected myocar-
dial ischaemia.32 However, there was no electrocardio-
graphic or echocardiographic evidence of ischaemia in
any of the study patients. Furthermore, patient selection
was designed to minimize the risk of confounding isch-
aemia, as only patients free from angiographic signs of
coronary artery disease were eligible.
Patients with diastolic dysfunction have an increased car-
diac morbidity and mortality2 3 and diastolic dysfunction
may contribute to perioperative congestive heart failure.
The present results indicated that, when given alone,
sevoflurane slightly ameliorates early diastolic function in
spontaneously breathing patients with pre-existing diastolic
dysfunction and that propofol had no effect. During IPPV
and balanced anaesthesia, diastolic function remained
impaired in the sevoflurane and propofol groups with no
differences between the study groups. The present findings
demonstrated ongoing impairment of diastolic function
under balanced anaesthesia but did not favour sevoflurane
or propofol as an agent that would be advantageous in
patients with pre-existing diastolic dysfunction. An outcome
study is required to confirm these results.
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